| chronic pain (diagnosis)
Mitigo vs Nucynta ER
Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).Deep comparison between: Mitigo vs Nucynta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNucynta has a higher rate of injection site reactions vs Mitigo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nucynta but not Mitigo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mitigo
Nucynta
At A Glance
Epidural/intrathecal infusion
Daily (continuous infusion)
Opioid agonist
Oral
Twice daily
Opioid agonist / NRI
Indications
- chronic pain (diagnosis)
- chronic pain (diagnosis)
- Diabetic peripheral neuropathy
Dosing
chronic pain (diagnosis) - Epidural Initial 3.5-7.5 mg/day (opioid-naive) or 4.5-10 mg/day (opioid-tolerant) via continuous epidural infusion; dose requirements may increase to 20-30 mg/day; titrate individually to adequate analgesia.
chronic pain (diagnosis) - Intrathecal Initial 0.2-1 mg/day (opioid-naive) or 1-10 mg/day (opioid-tolerant) via lumbar intrathecal infusion; intrathecal dose is typically 1/10 of epidural dose; doses above 20 mg/day should be used with caution.
chronic pain (diagnosis), Diabetic peripheral neuropathy Initiate at 50 mg orally every 12 hours in opioid-naive patients; titrate by 50 mg increments no more than twice daily every three days; maximum total daily dose 500 mg.
Moderate hepatic impairment Initiate at 50 mg no more than once every 24 hours; maximum 100 mg per day; regularly evaluate for respiratory and CNS depression.
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or absence of resuscitative equipment
- Concurrent use of MAOIs or use within the last 14 days
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to morphine (e.g., anaphylaxis)
- Infection at the neuraxial injection or microinfusion site
- Concomitant anticoagulant therapy (neuraxial administration)
- Uncontrolled bleeding diathesis (neuraxial administration)
- Any concomitant therapy or medical condition rendering epidural or intrathecal administration especially hazardous
- Significant respiratory depression
- Acute or severe bronchial asthma or hypercarbia in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to tapentadol or any other ingredient of the product
- Concurrent use of MAOIs or use within the last 14 days
Adverse Reactions
Most common Nausea, vomiting, constipation, pruritus, urinary retention, dizziness, headache, myoclonus, anxiety, confusion
Serious Respiratory depression, myoclonus, inflammatory masses, seizures, severe hypotension, adrenal insufficiency, serotonin syndrome, anaphylaxis
Postmarketing Androgen deficiency, hyperalgesia and allodynia, hypoglycemia, opioid-induced esophageal dysfunction
Most common (>=10%) Nausea, constipation, dizziness, headache, somnolence, vomiting
Serious Respiratory depression, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, neonatal opioid withdrawal syndrome
Postmarketing Hallucination, suicidal ideation, panic attack, anaphylaxis, androgen deficiency, hyperalgesia, allodynia, hypoglycemia, opioid-induced esophageal dysfunction
Pharmacology
Morphine is a full opioid agonist selective for the mu-opioid receptor that produces analgesia through CNS opioid receptors in the brain and spinal cord; it also causes respiratory depression by direct action on brain stem respiratory centers and reduces GI motility through smooth muscle effects.
Tapentadol is a centrally-acting synthetic analgesic that acts as a mu-opioid receptor (MOR) agonist and norepinephrine reuptake inhibitor (NRI); analgesia in animal models is derived from both properties, though the exact mechanism in humans is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mitigo
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (0/12)
Nucynta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Mitigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Nucynta
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (7/8)
Humana
Mitigo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Nucynta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Mitigo.
No savings programs available for Nucynta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MitigoView full Mitigo profile
NucyntaView full Nucynta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.